Skip to main content

Coronavirus Infections

Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study.

Nguyen-Tran H. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00349-4.

Published on 12/8/2025
SARS-CoV-2 genomic diversity and within-host evolution in individuals with persistent infection in the UK: an observational, longitudinal, population-based surveillance study.

Ghafari M. The Lancet Microbe 2025;:https://doi.org/10.1016/j.lanmic.2025.101154.

Published on 12/8/2025
Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study.

Holm Hansen C. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00380-9.

Published on 12/8/2025
Post COVID 19 resurgence of diphtheria in Kano, Nigeria: analysis of 18,320 cases.

Adamu Abbas M. eBioMedicine 2025;:https://doi.org/10.1016/j.ebiom.2025.105877.

Published on 12/8/2025
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial.

Thuluva S. The Lancet Regional Health - Southeast Asia 2025;:https://doi.org/10.1016/j.lansea.2025.100642.

Published on 12/8/2025
Characterisation of a persistent SARS-CoV-2 infection lasting more than 750 days in a person living with HIV: a genomic analysis.

Velasquez-Reyes JM. The Lancet Microbe 2025;:https://doi.org/10.1016/j.lanmic.2025.101122.

Published on 12/8/2025
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

Rumyantsev A. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103349.

Published on 12/8/2025
Excess mortality and hospitalisations associated with respiratory syncytial virus, influenza, and COVID-19 among adults in Denmark (2015–2024): a modelling study.

Egeskov-Cavling AM. The Lancet Regional Health – Europe 2025;:https://doi.org/10.1016/j.lanepe.2025.101396.

Published on 12/8/2025
Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.

Weinstein E. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00221-X.

Published on 12/8/2025
Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.

Ogbuagu O. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00238-5.

Published on 12/8/2025

...
12
13
14
15
16